Vicriviroc
Vicriviroc
Vicriviroc (pronounced as vi-kri-vi-roc) is an experimental antiretroviral drug that was under development for the treatment of HIV and AIDS. It belongs to a class of drugs known as CCR5 receptor antagonists, which work by blocking the CCR5 co-receptor on the surface of certain immune cells that HIV uses to enter and infect the cells.
Etymology
The name "Vicriviroc" is derived from the drug's mechanism of action. "Vi" stands for viral, "cri" for critical, and "viroc" for virological control, indicating the drug's role in controlling viral replication.
Mechanism of Action
Vicriviroc works by binding to the CCR5 receptor on the surface of certain immune cells, preventing HIV from attaching to and entering the cells. This mechanism of action is different from other antiretroviral drugs, which typically work by interfering with the replication of the virus inside the cells.
Clinical Trials
Vicriviroc has been studied in several clinical trials. In these trials, the drug was generally well tolerated and showed promising results in reducing the amount of HIV in the blood. However, the development of the drug was discontinued in 2010 due to business reasons.
Related Terms
External links
- Medical encyclopedia article on Vicriviroc
- Wikipedia's article - Vicriviroc
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski